AstraZeneca has been granted approval in the USA to market itsextended-release beta blocker Toprol-XL (metoprolol) for the treatment of stable, symptomatic heart failure of ischemic, hypertensive or cardiomyopathic origin. The approval has been granted based on the results of the MERIT-HF study (Marketletter November 23, 1998). The extended-release formulation is already approved for this indication in the European Union.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze